US › Healthcare

GeoVax Labs Inc (GOVX)

US · Healthcare · Biotechnology

$0.38-5.48%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-4.4M

EPS

$-0.97

EPS estimate

$-2.16

EPS came in at -0.97 against a street estimate of -2.16 — a beat of 55.1%.

Key statistics

Market cap

$4.2M

Forward P/E

9.7

P/B

2.42

Book value

$0.24

EPS (TTM)

$-5.58

52-week high

$17.78

52-week low

$0.45

50-day MA

$0.81

200-day MA

$2.49

Beta

3.65

Analyst view

Analysts rate GeoVax Labs Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $10.00.

Shareholding

Insiders

0.04%

Institutions

12.06%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	3.65%
Geode Capital Management, LLC	0.49%
Virtu Financial LLC	0.14%
Vanguard Fiduciary Trust Co	0.07%
UBS Group AG	0.06%
Tower Research Capital LLC	0.05%
Vanguard Capital Management, LLC	0.04%
BlackRock Inc	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GeoVax Labs Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.